Once-weekly exenatide as a treatment for Type 2 diabetes

Marisa B. Schauerhamer; Holly Gurgle; Carrie Mcadam-Marx

doi:10.1586/14779072.2015.1038242

Once-weekly exenatide as a treatment for Type 2 diabetes

Marisa B. Schauerhamer, Holly Gurgle, Carrie Mcadam-Marx

Research output: Contribution to journal › Article › peer-review

Abstract

Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications. As the disease progresses, most patients require combination therapy to achieve glucose control targets. Exenatide once weekly (EQW) is a glucagon-like peptide-1 receptor agonist approved in the United States in 2012 for use as a second-line agent to treat Type 2 diabetes mellitus. EQW has shown reductions in HbA1c and weight without causing an increased risk of hypoglycemia. This review will summarize the current clinical trial, observational study, and pharmacoeconomic analyses evaluating EQW and its impact on HbA1c and weight..

Original language	English (US)
Pages (from-to)	611-626
Number of pages	16
Journal	Expert review of cardiovascular therapy
Volume	13
Issue number	6
DOIs	https://doi.org/10.1586/14779072.2015.1038242
State	Published - Jun 1 2015
Externally published	Yes

Keywords

HbA1c
clinical trial
diabetes mellitus
exenatide
observational study . pharmacoeconomic evaluation
weight

ASJC Scopus subject areas

Internal Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1586/14779072.2015.1038242

Cite this

@article{daef60a9396f4c5a921a308ae6c77bdd,

title = "Once-weekly exenatide as a treatment for Type 2 diabetes",

abstract = "Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications. As the disease progresses, most patients require combination therapy to achieve glucose control targets. Exenatide once weekly (EQW) is a glucagon-like peptide-1 receptor agonist approved in the United States in 2012 for use as a second-line agent to treat Type 2 diabetes mellitus. EQW has shown reductions in HbA1c and weight without causing an increased risk of hypoglycemia. This review will summarize the current clinical trial, observational study, and pharmacoeconomic analyses evaluating EQW and its impact on HbA1c and weight..",

keywords = "HbA1c, clinical trial, diabetes mellitus, exenatide, observational study . pharmacoeconomic evaluation, weight",

author = "Schauerhamer, {Marisa B.} and Holly Gurgle and Carrie Mcadam-Marx",

note = "Publisher Copyright: {\textcopyright} 2015 Informa UK Ltd.",

year = "2015",

month = jun,

day = "1",

doi = "10.1586/14779072.2015.1038242",

language = "English (US)",

volume = "13",

pages = "611--626",

journal = "Expert review of cardiovascular therapy",

issn = "1477-9072",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Once-weekly exenatide as a treatment for Type 2 diabetes

AU - Schauerhamer, Marisa B.

AU - Gurgle, Holly

AU - Mcadam-Marx, Carrie

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications. As the disease progresses, most patients require combination therapy to achieve glucose control targets. Exenatide once weekly (EQW) is a glucagon-like peptide-1 receptor agonist approved in the United States in 2012 for use as a second-line agent to treat Type 2 diabetes mellitus. EQW has shown reductions in HbA1c and weight without causing an increased risk of hypoglycemia. This review will summarize the current clinical trial, observational study, and pharmacoeconomic analyses evaluating EQW and its impact on HbA1c and weight..

AB - Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications. As the disease progresses, most patients require combination therapy to achieve glucose control targets. Exenatide once weekly (EQW) is a glucagon-like peptide-1 receptor agonist approved in the United States in 2012 for use as a second-line agent to treat Type 2 diabetes mellitus. EQW has shown reductions in HbA1c and weight without causing an increased risk of hypoglycemia. This review will summarize the current clinical trial, observational study, and pharmacoeconomic analyses evaluating EQW and its impact on HbA1c and weight..

KW - HbA1c

KW - clinical trial

KW - diabetes mellitus

KW - exenatide

KW - observational study . pharmacoeconomic evaluation

KW - weight

UR - http://www.scopus.com/inward/record.url?scp=84929908594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929908594&partnerID=8YFLogxK

U2 - 10.1586/14779072.2015.1038242

DO - 10.1586/14779072.2015.1038242

M3 - Article

C2 - 26000560

AN - SCOPUS:84929908594

SN - 1477-9072

VL - 13

SP - 611

EP - 626

JO - Expert review of cardiovascular therapy

JF - Expert review of cardiovascular therapy

IS - 6

ER -

Once-weekly exenatide as a treatment for Type 2 diabetes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this